PAVmed PAVM

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.02 (-2.60%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

PAVmed (PAVM) Business Model and Operations Summary
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Key Insights

PAVmed (PAVM) Core Market Data and Business Metrics
  • Latest Closing Price

    $0.6468
  • Market Cap

    $10.89 Million
  • Average Trade Volume

    153,980 Shares
  • Total Outstanding Shares

    17.30 Million Shares
  • CEO

    Dr. Lishan Aklog M.D.
  • Total Employees

    107
  • IPO Date

    April 28, 2016
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Primary Exchange

    NASDAQ
  • Headquarters

    360 Madison Avenue, New York, NY, 10017

Earnings Reports

Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

Short Volume

Daily short volume activity identifies short-term trading pressure and potential price volatility

Short Interest

Short Interest

This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.

Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.

Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.

Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.

Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.

Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

Revenue Breakdown

Distribution of revenue across unique business segments & geographies

Historical Stock Splits

Execution DateSplit Amount

Historical Dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about PAVM from trusted financial sources